The Molecular Basis of Memory: Remembering and Forgetting

Gerard Marx¹* and Chaim Gilon²

¹MX Biotech Ltd., Jerusalem, Israel.
²Institute of Chemistry, Hebrew University, Jerusalem, Israel.

Correspondence: Gerard Marx, MX Biotech Ltd., Jerusalem, Israel, E-mail: Gerardmarx@gmail.com.

Received: 26 Jun 2022; Accepted: 31 Jul 2022; Published: 04 Aug 2022

Citation: Gerard Marx, Chaim Gilon. The Molecular Basis of Memory: Remembering and Forgetting. Int J Psychiatr Res 2022; 5(4): 1-10.

ABSTRACT

What lies between the vital physiology and pathology of cognitive aging?

To comprehend the brain’s mental function and dysfunction, we focus on memory, its formation and loss. Our expanded tripartite mechanism of memory involves the following compartments: Stimulated brain cells (neurons + glial cells) which secrete dopants (>10 metals and >80 neuro-transmitters (NTs) and glio-transmitters (GTs)) into the extracellular matrix (nECM/PNN) enveloping all brain cells, that performs as a “memory material”. The metal-centered complexes formed within the nECM/PNN are molecular correlates of cognitive units of information (cuinfo) that encode experience. The transmitters (NTs+GTs) embody emotive quality that elicit physiologic reactions from organs and glands to encode emotive states. As for decoding the cuinfo, aggregates (mosaics) of sensors (GPCR- and K-channel family proteins) within the lipid-bilayer comprising the cell membranes are capable of “reading” and integrating the cuinfo, transliterating them into an experiential mental state.

As to memory loss, aside from gross injuries or anatomical abnormalities, we look to molecular-level decay, which involve processes such as Toxicity or deficiency of trace metals, degradation of the nECM/PNN or it’s by enzymatic or redox (Fenton) reactions, uncontrolled lipid peroxidation (i.e. endocannabinoids) or autoimmune antibodies (i.e. anti- metallothionein) or lysozyme amyloid fibril formation. Interference with the optimal operation of the expanded tripartite mechanism of emotive memory is reflected by clinical features of memory loss in patients with degenerative disorders.

Keywords
Neuron, Glia, Extracellular matrix, Metals, Biomodulators, Emotions, Alzheimer, Degradation.

Abbreviations
Info: Information, cog-info: Cognitive Information, cuinfo:-Cognitive unit(s) of Information, nECM/PNN: Neural Extracellular Catrix/ Perineural Net, AD & PD: Alzheimer and Parkinsons diseases respectively.

Background
“Time’s the thief of memory.”
— Stephen King, The Gunslinger

“Nothing is ever really lost to us, as long as we remember it.”
— L.M. Montgomery, The Story Girl

“Memory is a part of the present. It builds us up inside; it knits our bones to our muscles and keeps our hearts pumping. It is memory that reminds our bodies to work, and memory that reminds our spirits to work: it keeps us who we are.”
— Gregory Maguire, Son of a Witch

“Death leaves a heartache no one can heal, Love leaves a memory no one can steal”.
(From an Irish headstone)
— Richard Puz, The Carolinian

“You shall blot out the memory of Amalek from under heaven.”
• Deuteronomy. 25:19.
There is a profound connection between the physiology of the body and the psychology of the neural net. To adopt a phrase from quantum mechanics, they are “entangled”. However, the mechanism of the brain’s unique mental talents (cognition, thought, and language) which involve memories and their loss remains opaque. We are in the dark, regarding the functional link between molecular physiology and mentality. This has been the perpetual enigma for philosophers and cognitive scientists [1-4], particularly acute for clinicians treating patients with memory deficits.

For example, some of the earliest symptoms of degenerative disorders such as Alzheimer disorder (AD) and Parkinson disorder (PD) are manifest as memory loss. Much has been published in the neurological literature about brain activity, particularly with the advent of non-invasive techniques (fMRI, CT scan, PET) [5-14]. However, we still lack a molecular-sealed organizing principle to describe the neural talent of recalling experience.

Evidence has linked memory disorders to a variety of primary causes such an unusual disposition of trace metals in the brain (notably toxicity or deficiency of trace metals i.e. Al, Cu, Fe, Mn, Zn), oxidative stress, immune reactions, lipid peroxidation and the release of β-amyloid peptides cleaved from precursor proteins associated with cellular tubulin, correlating with the onset of AD [15-20].

As with all aspects of normal animal development after birth, an optimal state is achieved with maturation, and then eventually decays. For humans, one expects memory to achieve peak performance upon maturity (~16-25 yrs), followed by gradual decay with age. There may be an accelerated rate of decay corresponding to a rapid loss of mental function, termed “dementia”. At some point during the aging of the neural creature (after mild cognitive impairment, MCI), a more rapid degradative process (Alz point) can begin to overwhelm the normal slow decay of the mental functioning, manifest as acute, irreversible loss of memory, as schematically represented in Figure 1.

![Figure 1: Hypothesized kinetics of memory loss in a normal ageing human and one with Alzheimer disorder (AD). The inset shows a set of fMRI scans of patient brains with mild cognitive impairment (MCI), followed by obvious reduction of brain tissue (Alz point) including loss of nECM (adapted from 14).](image-url)

However, to understand what went wrong, one needs to understand how the brain system functions under optimal conditions. Like all other body organs, one could consider that the memory function achieved by brain cell signaling must be based on known metabolic processes with available molecular components. At this stage of our evaluation, we avoid dealing with the memory of humans, as it involves language, itself a complex memory system. Rather, we wish to consider the universal memory/forgetting mechanism of non-verbal neural creatures.

A recent review considered the processes underlying the phenomenon of forgetting [21]. Presuming a forgetting mechanism based on synaptic contacts and molecular interactions, the review focused on problematic cell-cell interactions as itemized below:

- **Extinction** – Inhibition of conditioned response to stimulus by unassociated stimulus.
- **Interference** – of one memory trace by another, new memory impairing the recall of old memory.
- **Neurogenesis** – newly formed neurons integrated into the network disrupt pre-existing connections.
- **Aging** - decay of the brain cell signaling system.
- **Cell Death** - Specific brain cells encoding specific memory traces die.
- **De-potentiation** - Facilitated by β-amyloid peptide (Aβ) interference with NMDAR receptors, leading to memory decay.

Certain cell receptors and neurotransmitters were implicated in memory loss, namely:

- **AMPA receptors** - Glutamergic receptors; conductance of AMPARs present in synapse.
- **NMDA receptors** - Operating pores that permit the flow of Ca+2, Na+, K+
- **Enzymes** - Phosphatases (PP1, PP2A, CaMKIIa, PKM, MAPK, and kinases that affect phosphorylation reactions.
- **Neuromodulators** - Dopamine and other modulators.

Though presented as a molecular process, the above review [21] was essentially a description of cell signaling processes. We opine that one needs to consider a more detailed molecular mechanism for memory, to explain both its recall and its loss.

**Forgetting**

In our view, mechanism of remembering and forgetting are Janus-processes (Figure 2), one being the converse/inverse of the other.
To satisfy our need for a molecular basis for remembering linked to forgetting, we pursue an expanded version of our tripartite mechanism, as detailed below.

**Expanded Tripartite Mechanism of Memory**

In earlier parts of this series, we proposed a tripartite mechanism of memory, which involved the dynamic interactions of 3 physiologic compartments [22-27]. Here, we present an expanded version of this mechanism, as follows:

- **Brain cells**, notably neurons (highly extended cells that form long-distant circuits to muscles and glands via synaptic contacts) and glial cells, which surround neurons and their synaptic regions [28-32]. When stimulated, each cell type ejects biomodulating molecules (see dopants).

- **Extracellular matrix with perineural net (nECM/PNN) -** the anionic matrix encapsulating the brain cells. It is a polymeric hydrogel of hyaluronates incorporating lattices of chondroitin/heparan sulfates, which all embed the neurons and glial cells. The nECM/PNN functions as a “memory material” analogous to the matrix in computer memory chips [33-47].

- **Dopants –** metal cations, neurotransmitters (NTs) and glio-transmitters (GTs) [48-54] ejected by brain cells into the nECM/PNN, which serve as biomodulators which elicit physiologic responses and encode emotive cognitive information.

A general characteristic of a “memory material” used for memory chips is “its ability to store the (information) “state” of a system at a given time, and access such information, or part of it, at some later time. This “state” could be the spin polarization, or the doping profile, or some other physical characteristic of the system” [33].

For neural memory, the nECM/PNN around neural cells is the “memory material” which is doped with physiologically available metal cations and transmitter molecules (NTs/GTs) ejected by neurons and glial cells. Our tripartite mechanism provides a psychochemical rationale for encoding the neural memory system. The nECM performs as the ‘medium of representation’; the dopants (metals and NTs) are the ‘symbols of representation’ [55].

Specifically, metal-centered complexes are formed by the binding of ejected dopants (metal cations and NTs/GTs at electron-rich moieties (addresses) in the nECM/PNN enveloping the cells. Such NT/GT complexes are chemically more stable and more impervious to degradation reactions than proteins, thereby more available for recall [53]. Such complexes embody cognitive units of information (cuinfo) chemo-graphically represented below (Figure 3). They represent the “engram”, the physicality of the memory trace first proposed by Semon [56,57].

**Figure 2:** A drawing of the two-faced Roman god, Janus (Wikipedia).

**Figure 3 A,B:** Chemographic representations provides a chemographic shorthand for considering the nECM/PNN addresses and the chemical types of cuinfo that can be formed through metal binding and complexation with neuro-glio-transmitters (NTs/GTs) which are the molecular conveyors (elicitors and encoders) of emotions.

We previously employed the term “neuron” to indicate all cells within the brain, but here specifically include glia (astrocytes), which outnumber the neuron by factors of up to 10, depending on the anatomic compartment. We consider that all these cells,
which are in synaptic as well as non-synaptic contact with one another through the nECM/PNN operate as a “cloud” of cognitive information which permits of mentation based on memory. The metal-centered complexes are molecular correlates of cognitive units of information (cuinfo). The neurons and glial cells eject the contents of vesicles with metals and NTs/GTs to encode (i.e. “write”) cognitive information, Thus, memory is quantized, encoded and stored outside the brain cells, in their extracellular environment. We here and previous publications for detailed background and supportive evidence cited many publications.

The cells operate in “read” mode to decode and process the cuinfo stored within the nECM/PNN (Figure 4) with the millions of receptor-sensors (i.e. integrins, GPCR assemblies, K-channels and Acetylcholine receptors) expressed on their surface [24], which perform as “biologic micro-processors”.

The pathological features of AD/PD include:
- Protein degradation – amyloid peptide release and precipitation
- Lipid oxidation - excess circulating lipids
- Trace metal (Cu Fe Zn) - precipitation and mal-distribution
- Low metallothionein levels – autoimmune effects, poor metal transport.
- Poor insulin metabolism.

Q: Assuming that our above-described expanded tripartite mechanism is operative, how does it explain the clinical findings associated with such neuro-degenerative conditions?

A number of considerations are possible, as listed below:

**Redox Reactions**
Multivalent metals that participate in the encoding of metal complexes within the nECM that encode memory as cuinfo, notably Cu and Fe, could participate in ascorbate-instigated, metal-catalyzed, Haber-Weiss (Fenton) redox reactions [57-60] to release the deleterious OH radicals (Figure 5).

These redox reactions can instigate a number of effects including:
- Protein oxidation degradation and chain breaks resulting in release of amyloid peptides (which are toxic in their own right),
- Lipid oxidation,
- Condensation reactions,
- Release of trace metal cations due to modification of anionic binding moieties of the nECM.

The loss of memory by Alzheimer patients is an acute symptom of such a neuro-degenerative redox degradation of the nECM. It is associated with amyloid peptide release/toxicity as well as unbalanced metal (Al, Cu, Fe, Zn) metabolism [60-65]. Unlike enzymatic reactions, which are specific for one or another substrate (like a rifle), whereas the redox reactions can effectively destroy the entire locale in which they are generated (like a shotgun). Experimental examples of Fenton reactions were described for albumin and fibrinogen [65-70].

Oxidative cycling of multivalent metals via Fenton reactions with reductants, such as vit C or glutathione, which diffuse through the nECM to be absorbed by the cells (Figure 6). The tethered metals generate reactive OH’ radicals, which can degrade local components of the cells as well as the nECM/PNN. Within the cell, uncontrolled release of ascorbate and glutathione react with

---

**Figure 4**: Schematic representation of the tripartite mechanism, of emotive memory units (cuinfo) defined as the combination of nECM/PNN + dopants, surrounding the neuron. The receptors diffuse over the cell surfaces and are exposed to many addresses of the external nECM/PNN.

**Discussion**
The mystery of memory cannot be revealed unless it is reduced from philosophic speculation [1-4] to biochemical understanding. In keeping with other explanations of biologic processes, we have chosen the language and iconography of chemistry to comprehend the function called emotive memory, as discussed in detail in our previous reports [22-27]. Here, we wish to apply the lessons of the expanded tripartite mechanism, applied to the loss of memory experienced by individuals suffering from Alzheimer disorders (AD) or Parkinson disorder (PD).
amyloid precursor protein from cytoplasmic tubulin, releases amyloid peptides. The resultant altered shape of the cells corresponds to change in the local nECM.

Lipids that comprise cell membranes are also derivatized due to such redox reactions. Ancillary to these effects is the precipitation of metals, which no longer serve as dopants within the now-degraded nECM/PNN. The combined effects of such chemical degradation reactions is reflected by the composite loss of memory function.

**Fenton reaction degrading nECM/PNN**

extracellular
degrade

---

**Degradative Enzymes**

Enzymes permeating the matrix, including metallo-peptidases, can also degrade the nECM/PNN. Activation of such enzymes could cascade into significant degradation of the polymeric lattice, with resultant loss of memory units (cui\textsuperscript{info}) resulting in forgetting.

**Decreased Membrane Fluidity**

Mobile cell sensors (i.e. GPCR receptors), that are intercalated within the neural/glial membranes and diffuse therein [71,72], are responsible for the “read” function of brain cells. However, if the membrane fluidity were decreased, such as by incorporating hydrophilic blockers, such as endo-cannabinoids, this too would result in memory loss.

**Endo-cannabinoids (Endocan)**

Endocans are a type of neurotransmitters that are released by vesicles from the post-synaptic neuron into the synapse activating cannabinoid receptors in the postsynaptic neurons. The chemical makeup is very different from the other NTs, comprising a C-20 hydrocarbon domain (arachadonic acid derivative with variously placed double bonds) and a metal-chelating terminus [73,74] (Figure 7). Thus, Endocans can form ternary complex with cui\textsuperscript{info} in the nECM and be inserted into the membrane via their hydrophobic tail. This could alter the fluidity of the membrane lipid bilayer and the ability of the mobile sensors to access the nECM.

However, malfunction in the endo Endocan system cause excess release of Endocan both in the periphery and the central nervous system. This excess Endocan reaches the neural membrane in the memory regions of the brain (e.g. hippocampus) that are involved in memory “reading”. As the Endocans are bivalent regarding their chemical affinities, they can either bind to metals in cui\textsuperscript{info} or insert into the lipid bilayer of the membrane, causing loss of fluidity in GPCR movement essential for memory reading (Figure 8).
Endocans are unique and different from other fats in the sense that they can bind to both the metal in the cuinfo and be inserted into the adjacent membrane. Even without G-coupled protein receptors, one could consider that the Endocans could become inserted directly into the lipid bilayer of the cell membrane by hydrophobic affinity. For example, it is known that arachadonic acid binds to platelet membranes and is involved in the transformation of round, lentillic discs into multi-villi “cells” that attach to one another to instigate the blood coagulation cascade and form a platelet plug to stop bleeding. Thus, arachanoids can interact directly with lipid bilayers, somehow instigating shape change and synaptic plasticity in platelets and neurons respectively.

In addition, insertion of an Endocan molecule into the bilayer could inhibit the movement of the GPCR receptors, resulting in the inability to “read” the cuinfo encoded around the brain cells. In that in pathological cases excess EC could bound to a specific nECM address via its chelating head and stuck into the membrane around the GPCR ensemble in the adjacent membrane, slowing down or stopping the lateral movement of the GPCR ensemble [75,76], thereby preventing the reading of the cuinfo relevant to a particular memory…hence forgetting.

Metallothionein (MT) Problems
Histologic and other studies indicate that the MTs (with their load of cations) perform essential transport function of metals to reach the nECM/PNN, and permeate it to attach to the cell’s surface membrane. Overall, the MT can absorb and transport cations through the intestines into the blood, and permeate the blood-brain barrier, to reach the ECM/PNN and brain cells. One can also note that occasionally, antibodies to MT coincide with the onset of MT-related memory disfunctions [77-82].

Insulin Metabolism
Insulin modulates vasoreactivity, lipid metabolism, and inflammation. It also has a role in proteostasis, influencing clearance of the amyloid β peptide and phosphorylation of tau. Insulin resistance is a pathological condition in which cells fail to respond to the peptide insulin as observed in Alzheimer’s disease. Studies also depict a correlation with other neurodegenerative conditions (i.e. Parkinson’s disease and Huntington’s disease) [83-86].

Amyloid Formation
The loss of memory by Alzheimer patients is an early symptom of their neuro-degenerative state. It is associated with amyloid peptide release/toxicity as well as unbalanced metal (Al, Cu, Fe, Zn) distribution and metabolism.

Autophagy is the principal pathway for lysosomal degradation of obsolete proteins and organelles, associated with the formation of plaques. Imaging and histochemical techniques established that neurons are the origin of the vast majority of senile plaques in AD mouse models [87,88].

Vaso-circulation
K+ channel-mediated vasodilation could account for the clinical cerebrovascular presentation seen in AD patients [87]. Vasodilation in response to direct pharmacological activation of endothelial SK/IK channels was also reduced in AS model mice with reduced blood flow and crippled functional hyperemia.

Clinical Aspects
The brain’s “mentation circuit” comprises a complex of connected (associated, aggregated) receptors/sensor, described as mosaics/rafts, which perform a function unique to brain cell networks, characterized by “hub criteria” (connectivity & nodes), and clustering coefficient. Its malfunctioning has been implicated in multiple neurological disorders. Assuming an optimal performance of a human to be at age 18 years, one can schematize the gradual loss of mental function by a cascade of events. The relative memory function could be quantified by virtue of a standard memory test performed by the individual at different ages or compared to an average. The optimum in humans is assumed to be at 18-22 years, with initial rate of decay being slow and imperceptible. However, at the “Alz” time point, a sudden decrease in function occurs possibly associated with a specific triggering process. Below, we describe some of the triggering events might be and discuss how to address them.

However, how do the effects all relate to the normal brain memory process and its decay with age? A graphic summary of the many pathways by which memory loss could be associated with specific decay processes is presented in Figure 9.

Figure 9: Schematic representation of pathways whereby mentation could decay with time, manifest as memory loss.
Conclusion
The scientific enterprise is fueled by a hunger to understand the nature of things...for knowledge of matter, motion and mind. We know much about the vast cosmos and sub-atomic, quantum reality, but have huge gaps in our knowledge of how brain cells experience psychic effects such as emotive memory and the loss of such.

Rather, one must be aware that like a “Russian doll”, the workings of the brain are nested, operating at various scales, ranging from anatomic compartments, to complex neural networks. For the purposes of these discussions, we often employ the term “neuron” to include helper cells (astrocytes, glia). In any case, the localities around the cells (i.e. nECM/PNN) must be described in atomic or molecular detail to comprehend the process of emotive memory.

An explanation of how the brain generates memory requires not only an understanding of how it is anatomically organized in molecular detail but how it breaks down. Histologic conception of the brain cells must include reference to the environment in which the cells are cocooned.

During the past decade, three main hypotheses on the pathogenesis of AD have emerged that focus on different features of the disease:
- The amyloid cascade hypothesis.
- The metal ion hypothesis.
- The oxidative stress/insulin hypothesis.

The expanded tripartite mechanism permits us to consider these as different facets of a common process, as discussed above.

To slow down the decay of mental function, a number of lifestyle parameters have been suggested by diverse cultural models (Zen, Yoga, Chinese, vegan, Jewish, psychoanalytic re: Jung, Reich) [90-95], listed below.

Pillars to a Healthy Lifestyle
- Regular exercise
- Healthy diet (low fat, low sugar, low alcohol: adequate mineral intake, gluten/casein free diet)/fasting
- Quality sleep
- Stress management
- Active social life
- Intellectual stimulation
- Good sex
- Perform acts of kindness

We are all destined to metabolically decay and die (the ultimate form of forgetting) but we want to slow this down as much as possible. The behavioral guidelines reflect an intuited connection between physiology and psychology.

The material basis for neural memory has been the goal of neuroscientists from the time of Golgi and Cajal. The above-expanded tripartite mechanism permits one to consider memory loss such as in AD and other neurodegenerative diseases, in the context of dysfunctions of metal metabolism or the degradation of the nECM around brain cells.

I hope that some heuristic direction or clinical approaches to memory disorders might arise from the above biochemical description of emotive memory.

Acknowledgement
(By GM). Dedicated to my wife, my muse and collaborator, the artist Georgette Batlle (1940-2009), who never forgot a birthday. Thanks to friends, Lilly Rivlin (New York, N.Y.) and the late Bill Needle (Eastchester, N.Y.) for their early encouragement and financial support in the period 1980-1984.

Thanks also to my daughter Danae (Jerusalem) for filial support and critical reading of this manuscript.

References
1. Bergson H. Matter and Memory. Dover Publications, New York Translation from 1912 Edition. Allen & Co, London. 1908.
2. Ryle G. The Concept of Mind. University of Chicago Press, Chicago, IL. 1949.
3. Searle JR. The Mystery of Consciousness. The New York Review of Books, New York. 1997.
4. Shearcroft WFF. Matter, Man and Mind. MacMillan, NY. 1926.
5. Shcherbatykh I, Carpenter DO. The role of metals in the etiology of Alzheimer’s disease. J Alzheimers Dis. 2007; 11: 191-205.
6. Drago D, Bolognin S, Zatta P. Role of metal ions in the abeta oligomerization in Alzheimer’s disease and in other neurological disorders. Curr. Alzheimer Res. 2008; 5: 500-507.
7. Jomova K, Vondrakova D, Lawson M, et al. Metals oxidative stress and neurodegenerative disorders Mol. Cell Biochem. 2010; 345: 91-104.
8. Davilus ML, Bell CC, Berrettini W, et al. NIH state-of-the-science conference statement: Preventing Alzheimer’s disease and cognitive decline. NIH Consens State Sci Statements. 2010; 27: 1-30.
9. Small SA, Schobel SA, Buxton RB, et al. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat. Rev. Neurosci. 2011; 12: 585-601.
10. Benilova I, De Strooper B. Promiscuous Alzheimer amyloid: Yet another pathway. Science 2013; 341: 1354-1355.
11. Driscoll I, Hamilton DA, Petropoulos H, et al. The aging hippocampus: cognitive, biochemical and structural findings. Cereb Cortex. 2003: 13: 1344-1351.
12. Mishkin M, Suzuki WA, Gadian DG, et al. Hierarchical organization of cognitive memory. Phil. Trans. R. Soc. Lond. B. 1997; 352: 1461-1467.
13. Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous
system. Nature. 2006; 443: 796-802.
14. Wylie GR, Foxe JJ, Taylor TL. Forgetting as an active process: An fMRI investigation of item-method—directed forgetting. Cerebral Cortex 2008; 18: 670-682.
15. Kepp KP. Bioinorganic chemistry of Alzheimer’s disease. Chem. Rev. 2012; 112: 5193-5239.
16. Jellinger KA. The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. Int. Rev. Neurobiol. 2013; 110: 1-47.
17. Töugu V1, Tiikanen A, Palumaa P. Interactions of Zn(II) and Cu(II) ions with Alzheimer’s amyloid-beta peptide. Metal ion binding, contribution to fibrillation and toxicity. Metallomics. 2011; 3: 250-261.
18. Bindu GH, Rao GN. Mixed ligand complexes of essential metal ions with L-glutamine and succinic acid in sodium dodecyl sulfate-water mixtures. J. Serb. Chem. Soc. 2012: 77: 453-463.
19. Weiss B. The behavioral toxicology of metals. Fed. Proc. 1978; 37: 22-27.
20. Friberg L, Nordberg GF, Vouk VB, Eds. Handbook on the Toxicology of Metals. Elsevier Publishing, New York. 2007.
21. Moreno A. Molecular mechanisms of forgetting. Eur J Neurosci. 2021; 54: 6912-6947.
22. Marx G, Gilon C. The molecular basis of memory. ACS Chemical Neuroscience 2012; 3: 633-642.
23. Marx G, Gilon C. The molecular basis of memory. MBM Pt 2: The chemistry of the tripartite mechanism. ACS Chem Neurosci. 2013; 4: 983-993.
24. Marx G, Gilon C. The Molecular Basis of Neural Memory. Part 11. Chem-electric Write /Read Processes. J. Neurosurg. Imaging Techniques. 2020; 6: 283-301.
25. Marx G, Gilon C. Considerations of consciousness and emotive memory. J Psychol Neurosci. 2020; 2: 1-9.
26. Marx G, Gilon C. Addressing Searle’s “Problem of consciousness”. Int J Psychiatr Res. 2021; 4: 1-4.
27. Marx G, Gilon C. The Dimension of neural memory and consciousness. Int J Psychiatr Res 2022; 5: 1-9.
28. Hanani M, Verkhratsky A. (HU) Satellite Glial Cells and Astrocytes, a Comparative Review Neurochemical Research. 2021; 46: 2525-2537.
29. Field RD, Woo DH, Basser PJ. Glial regulation of the neuronal connectome through local and long-distance communication. Neuron. 2015; 86: 374-386.
30. Grumet M, Edelman GM. Neuron-glia cell adhesion molecule interacts with neurons and astroglia via different binding mechanisms. J Cell Biol. 1988; 106: 487-503.
31. Li D, Agulhon C, Schmidt E, et al. New tools for investigating astrocyte-to-neuron communication. Front Cell Neurosci. 2013; 7: 193.
32. Pereira Jr A, Furlan A. Astrocytes and human cognition: Modeling information integration and modulation of neuronal activity. Progress Neurobiol. 2010; 92: 405-420.
33. Di Venta, Massimiliano, Yuriy V. Pershin. “Memory materials: A unifying description”. Materialstoday. 2011; 14: 584-591.
34. Gallo V, Bertolotto A. Extracellular matrix of cultured glial cells: selective expression of chondroitin 4-sulfate by type-2 astrocytes and their progenitors. Exp Cell Res. 1990; 187: 211-223.
35. Iwata M, Carlson SS. A large chondroitin sulfate proteoglycan has the characteristics of a general extracellular matrix component of adult brain. J. Neurosci. 1993; 13: 195-207.
36. Ruoslahti E. Brain extracellular matrix. Glycobiology. 1996; 6: 489-192.
37. Sykova E. Extrasynaptic volume transmission and diffusion parameters of the extracellular space. Neuroscience. 2004; 129: 861-876.
38. Bonneh-Barkay D, Wiley CA. Brain extracellular matrix in neurodegradation. Brain Pathology. 2009; 19: 573-586.
39. Hrabetova S, Masri D, Tao L, et al. Calcium diffusion enhanced after cleavage of negatively charged components of brain extracellular matrix by chondroitinase ABC. J. Physiol. 2009; 587: 4029-4404.
40. Deepa SS, Carulli D, Galtrey C, et al. Composition of perineuronal net (PNN) extracellular matrix in rat brain: a different disaccharide composition for the net-associated proteoglycans. J Biol Chem. 2006; 281: 17789-1800.
41. Galtrey CM, Fawcett JW. The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res Rev. 2007; 54: 1-18.
42. Kolácná L, Bakesová J, Varga F, et al. Biochemical and biophysical aspects of collagen nanostructure in the extracellular matrix. Physiol Res. 2007; 56: S51-60.
43. Bachelard H, Carrera D, Jenkins H. Intercellular matrix molecules in the ageing brain. Exp Brain Res. 1982; 5: 67-75.
44. Thorne RG, Lakkaraju A, Rodriguez-Boulan E, et al. In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. Proc Natl Acad Sci USA. 2008; 105: 8416-8421.
45. Galtrey CM, Kwok JC, Carulli D, et al. Distribution and synthesis of extracellular matrix proteoglycans, hyaluronan, link proteins and tenascin-R in the rat spinal cord. Eur J Neurosci. 2008; 27: 1373-1390.
46. Zimmermann DR, Dours-Zimmermann MT. Extracellular matrix of the central nervous system: From neglect to challenge. Histochem Cell Biol. 2008; 130: 635-653.
47. Dityatev A, Seidenbecher CI, Schachner M. Compartmentalization from the outside: The extracellular matrix and functional microdomains in the brain. Trends in Neurosciences 2010; 33: 553-562.
48. Roshchin VV. Evolutionary considerations of neurotransmitters in microbial, plant, and animal cells. In: M. Lyte and P.P.E. Freestone (eds.), Microbial Endocrinology: Interkingdom Signaling in Infectious Disease and Health. 2010; 17-37.
49. Changeux JP. The Nicotinic acetylcholine receptor: The founding of the pentameric ligand- gated ion channel superfamily. J Biol Chem. 2012; 282: 40207-40216.
50. Martin DL. Synthesis and release of neuroactive substances by glial cells. GLIA. 1992; 5: 81-94.
51. Chiu SY, Kriegler S. Neurotransmitter-mediated signaling between axons and glial cells. GLIA. 1994; 11: 191-200.
integration in neuronal-astroglial networks. Neurochem Res. 2012; 37: 2326-2338.
54. Yonelinas AP, Ritchey M. The slow forgetting of emotional episodic memories: an emotional binding account. Trends Cogn Sci. 2015; 19: 259-267.
55. Vizi ES. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev. 2013; 52: 63-89.
56. Arbib MA. Warren McCullogh’s search for the logic of the nervous system. Perspect Biol Med. 2000; 43: 193-216.
57. Semon R. Mnemonic Psychology. G. Allen & Unwin, London. 1923.
58. Schacter DL. Forgotten Ideas, Neglected Pioneers: Richard Semon and the Story of Memory. Psychology Press, New York. 2001.
59. Kishida KT, Klann E. Reactive oxygen species, synaptic plasticity and memory. In: S.C. Veasey (Ed) Oxidative Neural Injury Ch 1. Humana Press. 2009; 1-28; 59.
60. Avshalumov MV, Chen BT, Rice ME. Mechanisms underlying H2O2-mediated inhibition of synaptic transmission in rat hippocampal slices. Brain Res. 2000; 882: 86-94.
61. Tögu Vl, Tiiman A, Palumaa P. Interactions of Zn(II) and Cu(II) ions with Alzheimer’s amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. Metallomics. 2011; 3: 250-261.
62. Le Page A, Dupuis G, Frost EH, et al. Role of the peripheral innate immune system in the development of Alzheimer’s disease. Experimental Gerontology. 2018; 107: 59-66.
63. Sutherland GT, Chami B, Youssef P, et al. Oxidative stress in Alzheimer’s disease: Primary villain or physiological by-product? Redox Rep. 2013; 18: 134-141.
64. Henke G, Möllmann H, Alves H. Comparative studies on the concentration of various trace elements in specific areas of the human brain using neutron activation analysis. Z Neurol. 1971; 199: 283-94.
65. Höck A, Demmel U, Schicha H, et al. Trace element concentration in human brain. Activation analysis of cobalt, iron, rubidium, selenium, zinc, chromium, silver, cesium, antimony and scandium. Brain. 1975; 98: 49-64.
66. Marx G, Chevion M. Site-specific modification of albumin by free radicals. Reaction with copper (II) and ascorbate. Biochem J. 1986; 236: 397-400.
67. Marx G. Immunological monitoring of Fenton fragmentation of fibrinogen. Free Radicals Res. Comm. 1991; 12: 517-520.
68. Marx G. Fibrinogen fragmentation by free radicals: Coagulation of fibrinogen with Cu (II) and ascorbate. Radiation Biology. E. Ricklis (Ed.) Weinheim Publishers. 1990; 691-698.
69. Markesbery W, Ehmann W, Hossain TI, et al. Instrumental neutron activation analysis of brain aluminum in Alzheimer disease and aging. Ann. Neurol. 1981; 10: 511-516.
70. Yoshida D, Ikeda Y, Nakazawa S. Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors. J Neuro-Oncol. 1993; 16: 109-115.
71. Popescu BFG, Nichol H. Mapping brain metals to evaluate therapies for neurodegenerative disease. CNS Neuroscience & Therapeutics. 2011; 17: 256-268.
72. Qin Z, Caruso JA, Lai B, et al. Trace metal imaging with high spatial resolution: Applications in biomedicine. Metallomics. 2011; 3: 28-37.
73. Briddon SJ, Jorge Gandia, Olavo B Amaral, et al. Plasma membrane diffusion of G protein-coupled receptor oligomers. Biochimica et Biophysica Acta. 2008; 1783: 2262-2268.
74. Borroto-Escuela DO, Brito I, Romero-Fernandez W, et al. The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components. Int. J. Mol. Sci. 2014; 15: 8570-8590.
75. Meshoulam R, Parker LA. The endocannabinoid system and the brain. Ann. Rev. Psychol. 2013; 64: 21-47.
76. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci. 2018; 19: 833.
77. Uchida Y, Takio K, Titani K, et al. The growth inhibitory factor that is deficient in the Alzheimer’s disease brain is a 68 amino acid metallothionein-like protein. Neuron 1991; 7: 337-347.
78. Suzuki KT, Imura N, Kimura M. (Eds) Metallothionein III; Biological roles and medical implications. Birkhäuser Velag. 1993.
79. Russo AF. Anti-metallothionein IgG and levels of metallothionein in autistic families. wiss Med. Wkly. 2008; 138: 70-77.
80. Ghanizadeh A. Gold implants and increased expression of metallothionein-I/II as a novel hypothesized therapeutic approach for autism. Toxicology. 2011; 283: 63-64.
81. Manso Y, Carrasco J, Comes G, et al. Characterization of the role of metallothionein-3 in an animal model of Alzheimer’s disease. Cell Molec. Life Sci. 2012; 69: 3683-3700.
82. Manso Y, Carrasco J, Comes G, et al. Characterization of the role of metallothionein-3 in an animal model of Alzheimer’s disease. Cell Mol Life Sci. 2012; 69: 3683-3700.
83. Kellar D, Craft S. Brain insulin resistance in Alzheimer’s disease and related disorders: Mechanisms and therapeutic approaches. Lancet Neurol. 2020; 19: 758-766.
84. Accardi G, Caruso C, Colonna G, et al. Can Alzheimer Disease Be a Form of Type 3 Diabetes? Rejuvenation Research. 2012; 15: 217-221.
85. Akhtar A, Sah SP. Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer’s disease. Neurochemistry International. 2020; 135: 104707.
Functionally linked potassium channel activity in cerebral endothelial and smooth muscle cells is compromised in Alzheimer’s disease PNAS. 2022; 119: e2204581119

90. Fritsch T, McClendon MJ, Smyth K, et al. Cognitive functioning in healthy aging: the role of reserve and lifestyle factors early in life. Gerontologist. 2007; 47: 307-322.

91. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008; 300: 1027-1037.

92. Miller KJ, Siddarth P, Gaines JM, et al. The memory fitness program: cognitive effects of a healthy aging intervention. Am. J. Geriatr. Psychiatry. 2012; 20: 514-523.

93. Nouchi R, Taki Y, Takeuchi H, et al. Beneficial effects of short-term combination exercise training on diverse cognitive functions in healthy older people: study protocol for a randomized controlled trial. Trials. 2012; 13: 200.

94. Miller KJ, Dye RV, Kim J, et al. Effect of a computerized brain exercise program on cognitive performance in older adults. Am. J. Geriatr. Psychiatry. 2013; 21: 655-663.

95. Bredesen D, Amos E, Canick J, et al. Reversal of cognitive decline in Alzheimer’s disease Aging (Albany NY). 2016; 8: 1250-1258.